Back to Screener

Elanco Animal Health Incorporated Common Stock (ELAN)

Price$23.13

Favorite Metrics

Price vs S&P 500 (26W)10.22%
Price vs S&P 500 (4W)-12.27%
Market Capitalization$11.55B
P/E Ratio (Annual)38.83x

All Metrics

P/CF (Annual)20.62x
Book Value / Share (Quarterly)$13.17
P/TBV (Annual)3.58x
Revenue Growth (3Y)2.25%
Cash Flow / Share (Quarterly)$0.57
Price vs S&P 500 (YTD)0.01%
Gross Margin (TTM)54.99%
Net Profit Margin (TTM)-4.92%
EPS (TTM)$-0.48
10-Day Avg Trading Volume4.30M
EPS Excl Extra (TTM)$-0.48
Revenue Growth (5Y)7.59%
EPS (Annual)$-0.47
ROI (Annual)-2.20%
Gross Margin (Annual)54.99%
Net Profit Margin (5Y Avg)-7.42%
Cash / Share (Quarterly)$1.10
P/E Basic Excl Extra (TTM)364.59x
Revenue Growth QoQ (YoY)12.16%
EPS Growth (5Y)29.95%
P/E Normalized (Annual)38.83x
ROA (Last FY)-1.74%
Revenue Growth TTM (YoY)6.22%
EBITD / Share (TTM)$1.09
ROE (5Y Avg)-5.05%
Operating Margin (TTM)-4.35%
Cash Flow / Share (Annual)$0.57
P/B Ratio1.76x
P/B Ratio (Quarterly)1.72x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)3.19x
Net Interest Coverage (TTM)3.08x
ROA (TTM)-1.73%
EV / EBITDA (TTM)27.87x
EPS Incl Extra (Annual)$-0.47
Current Ratio (Annual)2.17x
Quick Ratio (Quarterly)0.93x
3-Month Avg Trading Volume5.18M
52-Week Price Return167.63%
EV / Free Cash Flow (Annual)52.89x
P/E Incl Extra (TTM)364.59x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$6.32
P/S Ratio (Annual)2.45x
Asset Turnover (Annual)0.35x
52-Week High$27.72
Operating Margin (5Y Avg)-1.82%
EPS Excl Extra (Annual)$-0.47
CapEx CAGR (5Y)-2.35%
Tangible BV CAGR (5Y)8.49%
26-Week Price Return14.21%
Quick Ratio (Annual)0.93x
13-Week Price Return-2.68%
Total Debt / Equity (Annual)0.61x
Current Ratio (Quarterly)2.17x
Enterprise Value$15,021.214
Revenue / Share Growth (5Y)5.09%
Asset Turnover (TTM)0.35x
Book Value / Share Growth (5Y)-6.01%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.28x
Pretax Margin (Annual)-4.75%
Cash / Share (Annual)$1.10
3-Month Return Std Dev39.76%
Gross Margin (5Y Avg)55.61%
Net Income / Employee (TTM)$-0
EBITDA CAGR (5Y)28.45%
ROE (Last FY)-3.54%
Net Interest Coverage (Annual)3.08x
EPS Basic Excl Extra (Annual)$-0.47
P/FCF (TTM)32.72x
Receivables Turnover (TTM)5.62x
EV / Free Cash Flow (TTM)52.89x
Total Debt / Equity (Quarterly)0.61x
EPS Incl Extra (TTM)$-0.48
Receivables Turnover (Annual)5.62x
ROI (TTM)-2.15%
P/S Ratio (TTM)2.45x
Pretax Margin (5Y Avg)-6.89%
Revenue / Share (Annual)$9.50
Tangible BV / Share (Annual)$6.32
Forward P/E22.45x
Free OCF CAGR (5Y)70.08%
Price vs S&P 500 (52W)137.80%
P/E Ratio (TTM)364.59x
EPS Growth TTM (YoY)-82.48%
Year-to-Date Return2.65%
5-Day Price Return-0.98%
EPS Normalized (Annual)$-0.47
ROA (5Y Avg)-2.21%
Net Profit Margin (Annual)-4.92%
Month-to-Date Return-2.93%
Cash Flow / Share (TTM)$-0.92
EBITD / Share (Annual)$1.09
Operating Margin (Annual)-4.35%
LT Debt / Equity (Annual)0.57x
P/CF (TTM)20.62x
ROI (5Y Avg)-2.66%
P/E Excl Extra (TTM)364.59x
LT Debt / Equity (Quarterly)0.60x
EPS Basic Excl Extra (TTM)$-0.48
P/TBV (Quarterly)3.58x
P/B Ratio (Annual)1.72x
Inventory Turnover (TTM)1.28x
Pretax Margin (TTM)-4.75%
Book Value / Share (Annual)$13.17
Price vs S&P 500 (13W)-3.37%
Net Margin Growth (5Y)28.06%
Beta1.82x
P/FCF (Annual)40.67x
Revenue / Share (TTM)$9.78
ROE (TTM)-3.51%
52-Week Low$8.02

Analyst Recommendations

Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.27
4.27
4.27

Industry Peers — Pharmaceuticals(308)

SymbolP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
ELANElanco Animal Health Incorporated Common Stock
2.45x6.22%54.99%29.95%$23.13
LLYEli Lilly & Co.
13.08x44.70%83.04%27.59%$903.99
JNJJohnson & Johnson
5.94x7.87%67.95%14.90%$234.54
ABBVABBVIE INC.
6.04x8.57%71.62%-2.88%$208.99
MRKMerck & Co., Inc.
4.41x1.31%78.55%21.23%$115.46
AZNAstraZeneca PLC
5.28x8.63%81.31%21.88%$200.47
NVSNovartis AG
4.98x8.91%75.82%15.26%$149.73
NVONovo-Nordisk A/S
3.62x6.43%80.98%20.66%$40.93
ABTAbbott Laboratories
3.66x6.59%56.50%8.20%$95.47
PFEPfizer Inc.
2.47x-1.64%75.81%-3.51%$27.22
BMYBristol-Myers Squibb Co.
2.47x-0.22%72.63%$58.96

About

Elanco Animal Health is a global pharmaceutical company serving the companion and food animal markets with products sold in over 90 countries. The company's portfolio spans cattle, sheep, goats, swine, and companion animals, built through a combination of internal development and strategic acquisitions that have strengthened its market position.